TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Alfonso Quintás-Cardama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.